• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Moss Dana J was granted 616,667 shares, increasing direct ownership by 247% to 866,667 units (SEC Form 4)

    11/20/23 6:43:46 PM ET
    $NAVB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NAVB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Moss Dana J

    (Last) (First) (Middle)
    4995 BRADENTON AVE, SUITE 240

    (Street)
    DUBLIN OH 43017

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NAVIDEA BIOPHARMACEUTICALS, INC. [ NAVB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/16/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/16/2023 A 200,000(1) A $0 450,000 D
    Common Stock 11/16/2023 A 416,667(2) A $0 866,667 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares vest on the one-year anniversary of the Grant Date, subject to the Reporting Person's continuous service to the Company.
    2. Shares vest in three equal tranches, with the first tranche vesting on July 11, 2024 (the "Initial Vesting Date"), with the remaining tranches vesting ratably annually from the Initial Vesting Date over the following two years, subject to the Reporting Person's continuous service to the Company.
    Gioia Gentile on behalf of Dana J. Moss, by power of attorney 11/20/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NAVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAVB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split

      Navidea Biopharmaceucitals, Inc. extends deadline to implement a reverse stock split Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the extension of its authority to implement a reverse stock split of its common stock at a ratio of up to 1-for-50,000 shares. The Company originally received shareholder approval to amend its Certificate of Incorporation to authorize a reverse stock split at a ratio of up to 1-for-50,000 at a special meeting held on July 8, 2024. That authorization, which was initially set to expire on July 8, 2025, ha

      5/21/25 2:52:00 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets

      Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company") today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the "Section 382 Rights Plan"). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards ("NOLs") and other tax assets. As of December 31, 2024, Navidea had approximately $170 million in U.S. federal NOLs and approximately $9 million in R&D tax credits that may be used to offset future taxable income. However, these valuable tax attributes

      3/31/25 6:08:00 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

      Navidea Biopharmaceuticals, Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)" (ClinicalTrials.gov Identifier: NCT05246280) the "RA Trial." The purpose of the exploratory analysis was to optimize th

      7/3/24 4:30:00 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NAVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Scott John K Jr. disposed of 2,270 units of Series G Redeemable Preferred Stock, closing all direct ownership in the company (SEC Form 4)

      4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)

      12/5/23 6:26:20 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Moss Dana J was granted 616,667 shares, increasing direct ownership by 247% to 866,667 units (SEC Form 4)

      4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)

      11/20/23 6:43:46 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stefanelli Jill was granted 691,667 shares, increasing direct ownership by 277% to 941,667 units (SEC Form 4)

      4 - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Issuer)

      11/20/23 6:10:13 PM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $NAVB
    SEC Filings

    See more
    • SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

      EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

      2/1/24 12:15:04 AM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

      EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

      2/1/24 12:15:06 AM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Navidea Biopharmaceuticals Inc.

      EFFECT - NAVIDEA BIOPHARMACEUTICALS, INC. (0000810509) (Filer)

      2/1/24 12:15:11 AM ET
      $NAVB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care